Study reports novel surgical strategy for moyamoya disease

Notice: News releases are not subject to review by MedLink Neurology’s Editorial Board.

Moyamoya disease is a rare and progressive cerebrovascular disorder in which major arteries at the base of the brain gradually narrow, restricting blood flow and increasing the risk of stroke, brain hemorrhage, and cognitive decline. The condition, observed commonly in Asian populations, often affects adults during the most productive years of their lives. Although surgery to restore blood supply is considered the best treatment, neurosurgeons continue to refine techniques that can safely improve circulation while minimizing complications.

Now, a research team from China led by Professor Yongbo Yang from the Department of Neurosurgery at Nanjing University Medical School and Dr. Dong Zhang from the Department of Neurosurgery at Beijing Hospital evaluated a new concept called the superficial temporal artery patency concept (STAPC), which places preservation of the superficial temporal artery at the center of surgical planning. The results of their work were published in Volume 12, Issue 5 of the Chinese Neurosurgical Journal on February 26, 2026.

The superficial temporal artery is an important external vessel that can be redirected to nourish the brain when internal circulation has been compromised. “Instead of using a one-size-fits-all strategy, the STAPC method uses vessel diameter, blood-flow dynamics, and the condition of recipient brain arteries to guide decisions regarding whether to perform a direct bypass, an indirect bypass, or a combined procedure. The goal is to create durable collateral circulation while preserving long-term donor artery function,” explains Prof. Yang.

The researchers retrospectively reviewed outcomes in 303 adult patients treated at two Chinese medical centers between 2019 and 2021. Among them, 170 underwent combined superficial temporal artery-middle cerebral artery bypass with encephalo-duro-arterio-synangiosis, while 133 received indirect bypass surgery alone. The team used CT angiography to assess bypass patency, CT perfusion imaging to measure blood-flow recovery, and long-term clinical monitoring to detect recurrent stroke events.

The results were promising. More than 95% of bypasses remained open at both 3 and 12 months after surgery. Brain perfusion improved in nearly one-quarter of patients at 3 months and in over 40% at 1 year, with stronger gains in the combined bypass group. Across patients followed for a median of 50 months, recurrent stroke events occurred at an annual rate below 4%, suggesting sustained protection in a disease known for progressive vascular decline.

“Preserving the superficial temporal artery while matching the operation to each patient’s hemodynamic needs may help us improve both short-term recovery and long-term durability,” says Prof. Yang. “Our findings support a more individualized pathway for treating moyamoya disease.”

The study also highlights broader ripple effects for cerebrovascular surgery. Principles from STAPC—real-time flow assessment, vessel matching, and tailored reconstruction—may inform future approaches for complex stroke prevention, bypass refinement, and surgical planning technologies. Collaborations between neurosurgeons, imaging specialists, biomedical engineers, and data scientists could further improve patient selection and intraoperative decision-making.

In the short term, patients can benefit from safer operations, better blood-flow restoration, and fewer repeat strokes. Over the next 5 to 10 years, more personalized revascularization strategies could reduce disability, preserve independence, and lower long-term healthcare costs associated with stroke rehabilitation and chronic neurological care. Moreover, earlier interventions can also help working-age adults maintain a healthy quality of life.

Dr. Zhang adds, “For many clinicians, the challenge is not whether to revascularize but how to choose the right operation for the right patient. Our concept provides a practical framework that can continue to evolve with better imaging and multicenter evidence.”

Although the team notes that future prospective randomized studies are still needed, the current findings suggest that STAPC represents an important next step in individualized brain revascularization for patients with moyamoya disease.

Source: News Release
Chinese Neurosurgical Journal
May 11, 2026